Key facts
- This page summarizes Slanix Paul Alex's Form 3 filing for ProMIS Neurosciences Inc. (PMN).
- 0 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 24 Oct 2025, 16:30.
Slanix Paul Alex - 22 Oct 2025 Form 3 Insider Report for ProMIS Neurosciences Inc. (PMN)
- Reporting relationship
- Director
- Issuer ticker
- PMN
- Reported as of
- 22 Oct 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 24 Oct 2025, 16:30:21 UTC
- Next SEC filing
- 22 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Max A. Milbury, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Slanix Paul Alex filed Form 3 for ProMIS Neurosciences Inc. (PMN) on 24 Oct 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002092283
Primary reporting owner
Alex Slanix Paul
- Relationship
- Director
- Address
- C/O PROMIS NEUROSCIENCES INC., SUITE 200, 1920 YONGE STREET, TORONTO, ONTARIO, CANADA
- Signature
- /s/ Max A. Milbury, Attorney-in-Fact
- Signature date
- 24 Oct 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PMN
holding
Common Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,058,738
- Date
- 22 Oct 2025
- Ownership
- See Footnote
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PMN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Oct 2025
- Ownership
- See Footnote
- Underlying class
- Common Shares
- Underlying amount
- 174,759
- Exercise price
- $0.0100
- Footnotes
- F1, F2
PMN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Oct 2025
- Ownership
- See Footnote
- Underlying class
- Common Shares
- Underlying amount
- 1,066,674
- Exercise price
- $1.75
- Footnotes
- F1
PMN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Oct 2025
- Ownership
- See Footnote
- Underlying class
- Common Shares
- Underlying amount
- 1,100,000
- Exercise price
- $0.0100
- Footnotes
- F1, F2
PMN
holding
Derivative
Warrants
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Oct 2025
- Ownership
- See Footnote
- Underlying class
- Common Shares
- Underlying amount
- 7,348,604
- Exercise price
- $1.25
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These securities are held of record by Ally Bridge MedAlpha Master Fund L.P. The Reporting Person is a director of the Issuer and an employee of Ally Bridge Group (NY) LLC, which manages the investments of Ally Bridge MedAlpha Master Fund L.P. The Reporting Person disclaims beneficial ownership of such securities for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such securities are beneficially owned by him for Section 16 or any other purpose.
Footnote F2
The warrants will expire when exercised in full.
SEC remarks
Exhibit 24 - Power of Attorney